Lennox R, Flatt PR, Gault VA
Cardiovascular protection: Some GLP-1 medications have been shown to reduce the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death in people with type 2 diabetes, particularly those with existing cardiovascular disease or multiple risk factors
Tirzepatide's greater glucose-lowering effect compared to semaglutide means hypoglycemia risk may increase, especially if you are also taking sulfonylureas or insulin
Changes in Appetite and Eating Patterns Because semaglutide reduces appetite, some patients eat less frequently or consume fewer carbohydrates than their body is used to
There is no direct evidence that semaglutide worsens bipolar disorder symptoms, but there are a few points to consider: Impact on the Central Nervous System (CNS) : Semaglutide primarily works on blood sugar levels and appetite by targeting GLP-1 receptors